Im­mu­nic shares cut in half as biotech dumps ul­cer­a­tive col­i­tis af­ter PhII fail

Fails can be­come cost­ly, so in an ef­fort to stem loss­es, Im­mu­nic and CEO Daniel Vitt have de­cid­ed to throw in the tow­el on ul­cer­a­tive col­i­tis af­ter a Phase II miss.

Im­mu­nic re­port­ed Wednes­day that its lead as­set, vid­ofludimus cal­ci­um, failed a Phase II tri­al for the in­di­ca­tion, miss­ing the pri­ma­ry end­point of clin­i­cal re­mis­sion in 30 and 45 mg/day dos­es when test­ed against place­bo af­ter 10 weeks. Ad­di­tion­al­ly, no “mean­ing­ful dif­fer­ences” be­tween three dif­fer­ent dose lev­els were ob­served in the tri­al called CAL­DOSE-1, nor be­tween any of the sec­ondary end­points such as en­do­scop­ic heal­ing or symp­to­matic re­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER